ARS Pharmaceuticals (SPRY) to Release Earnings on Thursday

ARS Pharmaceuticals (NASDAQ:SPRY) is projected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect ARS Pharmaceuticals to post earnings of ($0.09) per share and revenue of $15.46 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

ARS Pharmaceuticals Price Performance

SPRY opened at $11.44 on Tuesday. ARS Pharmaceuticals has a fifty-two week low of $7.55 and a fifty-two week high of $18.51. The business has a 50-day moving average of $11.97 and a 200-day moving average of $13.05. The company has a market capitalization of $1.11 billion, a PE ratio of -22.43 and a beta of 1.03.

Analysts Set New Price Targets

A number of research firms have recently weighed in on SPRY. William Blair reaffirmed an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Monday, March 3rd. Oppenheimer initiated coverage on ARS Pharmaceuticals in a report on Monday, February 10th. They set an “outperform” rating and a $40.00 price objective on the stock. Scotiabank initiated coverage on ARS Pharmaceuticals in a report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Leerink Partners increased their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Finally, Raymond James increased their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $31.00.

Insider Transactions at ARS Pharmaceuticals

In other news, Director Laura Shawver sold 49,600 shares of ARS Pharmaceuticals stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total transaction of $556,016.00. Following the sale, the director now owns 210,346 shares of the company’s stock, valued at approximately $2,357,978.66. This trade represents a 19.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have sold 149,600 shares of company stock valued at $1,726,516. 40.10% of the stock is owned by corporate insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.